Breast Cancer Foundation NZ
STARTRK-2
Recruiting
Updated: June 9, 2021
This is an open-label, multicenter, global phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3 or ROS1 gene fusion.
Patients will be assigned to different baskets according to tumor type and gene fusion.
Lung cancer and colorectal cancer are the main tumours of interest, but breast cancer solid tumours will also be included.
Australia
Flinders Medical Centre, Adelaide
Austin Hospital, Melbourne
Liverpool Hospital, Sydney
Austin Hospital, Melbourne
Liverpool Hospital, Sydney
Contact:
Austin Hospital: Kellie ConnellanIf you think you might be a candidate for this trial, use the contact details supplied, or talk to your doctor.
Want to access a trial that's not in your area? It's not always possible, but if you're interested, email us at intouch@bcf.org.nz
Similar clinical trials
For Advanced Breast Cancer
Are we out of date? If you have updated or new information about a trial, we’d be grateful if you’d share it with us – email your update to intouch@bcf.org.nz
Interested in a clinical trial?
Subscribe for updates & stay in the loop with new studies.